Havana, April 12 (ACN) Experts with the BioCubaFarma Biotech conglomerate said on Monday that the second dose of the locally developed COVID-19 vaccines Soberana 02 and Abdala keep advancing as scheduled.
A controlled interventional study closed the administration of a first dose to 75 thousand volunteers in a first stage, according to BioCubaFarma.
Meanwhile, Over 22 thousand Cubans have already received the second dose during phase III trials for Abdala and over 4 500 have got the shot of Soberana 02.
Cuba expects to immunize its population in the coming months against COVID-19 and also contribute to the immunization of other nations.
Cuban COVID-19 Vaccines Keep Progressing
Nos reservamos el derecho de no publicar los comentario que incumplan con las normas de este sitio